Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448

Targeting hypoxia in cancer therapy

Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874

L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity

Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.031 · Cited by 1,775

Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1

Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370

Oxygen-carrying nanoemulsions and respiratory hyperoxia eliminate tumor hypoxia–induced immunosuppression

Halpin-Veszeleiova, K., Mallouh, M. P., Williamson, L. M., Apro, A. C., Botticello-Romero, N. R., Bahr, C., Shin, M., Ward, K. M., Rosenberg, L., Ritov, V. B., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174675 · Cited by 28

Engineering TME-gated inducible CAR-T cell therapy for solid tumors

Nguyen, H., Kim, B., Myers, J., Yan, H., Kumar, S., Eid, S. K., Wang, W., Huang, A. Y.-C., & Liang, F. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.037 · Cited by 20

Prognostic and Predictive Relevance of Tumor-Infiltrating Lymphocytes in Squamous Cell Head–Neck Cancer Patients Treated with Radical Radiotherapy/Chemo-Radiotherapy

Koukourakis, I. M., Gkegka, A. G., Xanthopoulou, E. T., Nanos, C., Giatromanolaki, A. N., & Koukourakis, M. I. (2022) · Current Oncology · doi:10.3390/curroncol29060342 · Cited by 20

Optimizing mitochondria function in immune cells: implications for cancer immunotherapy

Li, H., Jin, W., Liu, J., Zhou, Y., Shan, X., Zhang, Y., Kou, Y., Deng, C., Jin, C., Kuang, J., et al. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.006 · Cited by 19

Mechanisms of HIF-driven immunosuppression in tumour microenvironment

Bandopadhyay, S., & Patranabis, S. (2023) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-023-00186-z · Cited by 20

The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy

Cruz‐Bermúdez, A., Briviesca, R. L., Casarrubios, M., Sierra‐Rodero, B., & Provencio, M. (2021) · Biomedicines · doi:10.3390/biomedicines9040361 · Cited by 20

Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide

Hunter, F. W., Devaux, J. B. L., Meng, F., Hong, C. R., Khan, A., Tsai, P., Ketela, T. W., Sharma, I., Kakadia, P. M., Marastoni, S., et al. (2019) · Molecular Pharmacology · doi:10.1124/mol.118.115196 · Cited by 18

Hyperoxia Alters Ultrastructure and Induces Apoptosis in Leukemia Cell Lines

Bels, D. D., Tillmans, F., Corazza, F., Bizzarri, M., Germonpré, P., Radermacher, P., Orman, K. G., & Balestra, C. (2020) · Biomolecules · doi:10.3390/biom10020282 · Cited by 18

Deciphering the tumour immune microenvironment cell by cell

Nabhan, M., Egan, D., Kreileder, M., Zhernovkov, V., Timosenko, E., Slidel, T. W. F., Dovedi, S. J., Glennon, K., Brennan, D. J., & Kölch, W. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100383 · Cited by 17

In silico analysis of hypoxia activated prodrugs in combination with anti angiogenic therapy through nanocell delivery

Meaney, C., Rhebergen, S., & Kohandel, M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007926 · Cited by 17

Simultaneous Engagement of Tumor and Stroma Targeting Antibodies by Engineered NK-92 Cells Expressing CD64 Controls Prostate Cancer Growth

Hintz, H. M., Snyder, K. M., Wu, J., Hullsiek, R., Dahlvang, J. D., Hart, G. T., Walcheck, B. K., & LeBeau, A. M. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0178 · Cited by 18

Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development

Wei, Q., & Taskén, K. (2022) · Biochemical Journal · doi:10.1042/bcj20210233 · Cited by 19

Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation

Cheng, G., Hardy, M., You, M., & Kalyanaraman, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-08984-6 · Cited by 17

The promise of targeting heme and mitochondrial respiration in normalizing tumor microenvironment and potentiating immunotherapy

Akter, Z., Salamat, N., Ali, M. Y., & Li, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1072739 · Cited by 17

Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment

Wang, P., Wang, X., Man, C., Gong, D., & Fan, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200619 · Cited by 17

Mesenchymal stem cell-derived exosomes for management of prostate cancer: An updated view

Arab, F. L., Hoseinzadeh, A., Hafezi, F., Mohammadi, F. S., Zeynali, F., Tehran, M. H., & Rostami, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112171 · Cited by 17

Resolving the HIF paradox in pancreatic cancer

Fuentes, N. R., Phan, J. L., Huang, Y., Lin, D., & Taniguchi, C. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.033 · Cited by 16

Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model

Ager, C. R., Obradović, A., Arriaga, J. M., Chaimowitz, M. G., Califano, A., Abate-Shen, C. T., & Drake, C. G. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0637 · Cited by 16

Identification of m6A modification patterns and development of m6A–hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer

Shen, X. P., Zhong, J., He, J., Han, J., & Chen, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978092 · Cited by 16

Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies

Faraj, J. A., Al-Athari, A. J. H., Mohie, S. E. D., Kadhim, I. K., Jawad, N. M., Abbas, W. J., & Jalil, A. T. (2022) · Medical Oncology · doi:10.1007/s12032-022-01842-5 · Cited by 16

The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise

Che, J., Liu, Y., Liu, Y., Song, J., Cui, H., Feng, D., Tian, A., Zhang, Z., & Xu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544882 · Cited by 15

Turning Fluvastatin into a supramolecular immuno-sensitizer towards augmented tumor immunotherapy

Ma, F., Liu, T., Yang, W., You, W., He, W., Yan, J., & Liu, W. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135310 · Cited by 15

Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer

Smith, V., Lee, D. C. H., Reardon, M., Shabbir, R., Sahoo, S., Hoskin, P., Choudhury, A., Illidge, T., & West, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108956 · Cited by 15

Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin)

Genoud, V., Espinoza, F. I., Marinari, E., Rochemont, V., Dietrich, P., McSheehy, P. M. J., Bachmann, F., Lane, H. A., & Walker, P. R. (2021) · JCI Insight · doi:10.1172/jci.insight.142980 · Cited by 15

Effect of bead size and doxorubicin loading on tumor cellular injury after transarterial embolization and chemoembolization in a rat model of hepatocellular carcinoma

Cortés, A. C., Nishiofuku, H., Polak, U., Minhaj, A. A., Lopez, M. S., Kichikawa, K., Qayyum, A., Whitley, E. M., & Avritscher, R. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102465 · Cited by 15

Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives

Rai, V. (2025) · Biomolecules · doi:10.3390/biom15060751 · Cited by 14

Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration

Liu, A. J., Gammon, S. T., Pisaneschi, F., Boda, A. R., Ager, C. R., Piwnica-Worms, D. R., Hong, D. S., & Curran, M. A. (2023) · JCI Insight · doi:10.1172/jci.insight.169150 · Cited by 15

Increased PIEZO1 Expression Is Associated with Worse Clinical Outcomes in Hormone-Receptor-Negative Breast Cancer Patients

Poole, R. A., Wang, Q., Ray, A., Takabe, K., Opyrchal, M., & Katsuta, E. (2024) · Cancers · doi:10.3390/cancers16040683 · Cited by 15

Mechanisms of HIF1A-mediated immune evasion in gastric cancer and the impact on therapy resistance

Qi, H., Ma, X., Ma, Y., Jia, L., Liu, K., & Wang, H. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09917-x · Cited by 14

Proteome dynamics analysis identifies functional roles of SDE2 and hypoxia in DNA damage response in prostate cancer cells

Luo, A., Gong, Y., Kim, H., & Chen, Y. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa010 · Cited by 14

Sufficient numbers of anti-tumor T cells is a condition of maximal efficacy of anti-hypoxia-A2-adenosinergic drugs during cancer immunotherapy

Sitkovsky, M. V. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.07.011 · Cited by 14

Galectin expression detected by 68Ga-galectracer PET as a predictive biomarker of radiotherapy resistance

Lu, D., Zhou, H., Li, N., Wang, Y., Zhang, T., Wang, F., Liu, N., Zhu, H., Zhang, J., Yang, Z., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05711-1 · Cited by 14

Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy

Li, W., Zhan, M., Quan, Y., Wang, H., Hua, S., Li, Y., Zhang, J., Lu, L., & Cui, M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106227 · Cited by 14

Hypoxia-inducible lentiviral gene expression in engineered human macrophages

Chinn, H. K., Gardell, J. L., Matsumoto, L. R., Labadie, K. P., Mihailovic, T. N., Lieberman, N. A. P., Davis, A. D., Pillarisetty, V. G., & Crane, C. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003770 · Cited by 13

HLA-class-I expression loss, tumor microenvironment and breast cancer prognosis

Giatromanolaki, A. N., Michos, G. D., Xanthopoulou, E. T., & Koukourakis, M. I. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104816 · Cited by 13

Manganese-based nanomaterials promote synergistic photo-immunotherapy: green synthesis, underlying mechanisms, and multiple applications

Cao, Y., Li, Y., Ren, C., Yang, C., Hao, R., & Mu, T. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02844e · Cited by 13

Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities

Hartley, F., Ebert, M. A., & Cook, A. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70030 · Cited by 15

Approaches for boosting antitumor immunity in prostate cancer therapy: A comprehensive review on drugs, products, and nanoparticles

Chen, D., & Hu, Y. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105048 · Cited by 12

Smart multi‐functional aggregates reoxygenate tumor microenvironment through a two‐pronged strategy to revitalize cancer immunotherapy

Zhang, Y., Liang, L., Li, H., Cao, Y., Du, M., Li, X., Wang, M., Wang, J., Yao, Y., Zhang, S., et al. (2024) · Aggregate · doi:10.1002/agt2.545 · Cited by 13

Rational design of an oxygen-enriching nanoemulsion for enhanced near-infrared laser activatable photodynamic therapy against hypoxic tumors

Hong, L., Wang, J., Geng, J.-X., Zhao, Y., Zhou, G., Zhang, J., Liu, L., & Qu, J. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111500 · Cited by 12

ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration

Cui, X., Yu, H., Yao, J., Li, J., Li, Z., & Jiang, Z. (2022) · BMC Cancer · doi:10.1186/s12885-022-10424-7 · Cited by 13

Heterogeneity and the tumor microenvironment in neuroendocrine prostate cancer

Brady, L., & Nelson, P. S. (2022) · Journal of Endocrinology · doi:10.1530/joe-22-0211 · Cited by 12

Hypoxia‐ and pH‐Responsive Metal‐Phenolic Network‐Engineered Ferroptosis‐Immuno Microspheres for Transarterial Chemoembolization in Hepatocellular Carcinoma

Li, Q., Shi, J., Ruan, X., Zhang, L., Fu, R., Hidayat, K., Qin, L., Xu, J., Chong, Y., & Hu, C. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202510798 · Cited by 11

Role of ubiquitin specific proteases in the immune microenvironment of prostate cancer: A new direction

Guo, J., Zhao, J., Sun, L., & Chen, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.955718 · Cited by 11

Advances in macrophage and T cell metabolic reprogramming and immunotherapy in the tumor microenvironment

Cheng, H., & Zheng, Y. (2024) · PeerJ · doi:10.7717/peerj.16825 · Cited by 13

Radiomics‐Based Unsupervised Clustering Identifies Subtypes Associated With Prognosis and Immune Microenvironment in Clear Cell Renal Cell Carcinoma: A Multicenter Study

Guo, Y., Gong, B., Li, Y., Lou, J., Shan, S., Zhang, X., Lü, Q., Zhu, D., Sun, Q., Miao, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202506165 · Cited by 11

Immunometabolic reprogramming in lung cancer: interplay between immune and stem-like cells in immune checkpoint inhibitor resistance

Sung, J., & Kim, E. T. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07244-1 · Cited by 11

Cellular diversity through space and time: adding new dimensions to GBM therapeutic development

Johnson, A., & López-Bertoni, H. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1356611 · Cited by 11

Radiotherapy plus immune checkpoint inhibitor in prostate cancer

Li, T., Qian, X., Liu, J., Xue, F., Luo, J., Yao, G., Yan, J., Liu, X., Xiao, B., & Li, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210673 · Cited by 10

Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy

Semenza, G. L. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100075 · Cited by 10

Tumor-associated endothelial cells in tumor immune escape and immunotherapy: multifaceted roles and treatment approaches

Zheng, T., Yu, X., Yu, C., Xu, W., Fan, Z., Zhou, Y., Li, C., Wan, J., Jin, C., Jin, X., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00883-y · Cited by 10

Identification of a Hypoxia-Related Gene Signature for Predicting Systemic Metastasis in Prostate Cancer

Xia, H., Wang, J., Guo, X., Lv, Z., Liu, J., Yan, Q., Liu, M., & Wang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696364 · Cited by 10

Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment

Mudassar, F., Shen, H. M., Cook, K. M., & Hau, E. K. C. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13416 · Cited by 10

T cells in the peritoneum

Rathod, S. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.013 · Cited by 10

Nanodelivery Systems Delivering Hypoxia-Inducible Factor-1 Alpha Short Interfering RNA and Antisense Oligonucleotide for Cancer Treatment

Yan, Y., Li, H., Yao, H., & Cheng, X. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.932976 · Cited by 10

Leveraging hypoxia in triple-negative breast cancer as a promising treatment strategy

Bhise, K., Gavande, N. S., & Iyer, A. K. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103761 · Cited by 10

Advances in Nanoplatforms for Immunotherapy Applications Targeting the Tumor Microenvironment

Zhang, N., Zhou, J., Li, S., Cai, W., Ru, B., Hu, J., Liu, W., Liu, X., Tong, X., & Zheng, X. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00846 · Cited by 11

Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis

Fahmy, O., Alhakamy, N. A., Khairul‐Asri, M. G., Ahmed, O. A. A., Fahmy, U. A., Fresta, C. G., & Caruso, G. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm12010008 · Cited by 11

Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?

Simula, L., Ollivier, E., Icard, P., & Donnadieu, E. (2022) · Cells · doi:10.3390/cells11111854 · Cited by 10

Ex Vivo Evaluation of Combination Immunotherapy Using Tumor‐Microenvironment‐on‐Chip

Mu, H., Lin, C., Chu, L., Lin, Y., Li, J., Liu, C., Huang, H., Cheng, S., Lee, T., Lee, H. M., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302268 · Cited by 9

Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma

Wang, B., Qi, F.-Z., Chen, P., Qian, L.-M., Su, H.-S., Wang, Y., Wang, C.-H., Hou, Y., Zhang, Q. H., Li, D., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.92211 · Cited by 9

Advances in Nanotechnology-Based Cisplatin Delivery for ORL Cancers: A Comprehensive Review

Morgovan, A. I., Boia, E. R., Motofelea, A. C., Orasan, A., Negru, M. C., Guran, K., Para, D. M., Sandu, D., Ciocani, S., Sitaru, A. M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115261 · Cited by 9

Tumour- and Non-Tumour-Associated Factors That Modulate Response to PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer

Khalil, M., & Tsao, M. (2025) · Cancers · doi:10.3390/cancers17132199 · Cited by 9

Analyses of hypoxia-related risk factors and clinical relevance in breast cancer

Li, Y., Yu, H., Han, X., & Pan, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1350426 · Cited by 9

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3

Abbattista, M. R., Ashoorzadeh, A., Guise, C. P., Mowday, A. M., Mittra, R., Silva, S., Hicks, K. O., Bull, M. R., Jackson-Patel, V., Lin, X., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14121231 · Cited by 9

Multicellular tumor spheroids of LNCaP-Luc prostate cancer cells as in vitro screening models for cytotoxic drugs.

Jouberton, E., Voissière, A., Penault-Llorca, F. M., Cachin, F., & Miot-Noirault, É. (2022) · PubMed Central · Cited by 9

A checkpoint on innate myeloid cells in pulmonary arterial hypertension

Bryant, A. J., Fu, C., Lu, Y., Brantly, M., Mehrad, B., Moldawer, L. L., Brusko, T. M., Brittain, E. L., West, J. D., Austin, E. D., et al. (2018) · Pulmonary Circulation · doi:10.1177/2045894018823528 · Cited by 9

Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study

Yousef, E. H., Gayar, A. M. E., & El‐Magd, N. F. A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03530-9 · Cited by 8

Subtypes of tumor-associated neutrophils and their roles in cancer immunotherapy

Chu, X., Pu, N., Yang, X., Xie, Y., Liu, L., & Jin, Y. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104763 · Cited by 8

Microglial Membrane‐Coated Biomimetic Nanoplatform for Enhanced Blood–Brain Barrier Penetration and Targeted Photodynamic Therapy in Orthotopic Glioblastoma

Li, J., Xu, X., Zhao, Y., Wu, X., Chen, S., Xu, J., Xiao, R., Tang, J. P., Hong, X., Chen, S., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502808 · Cited by 8

Metabolic reprogramming in the post-metastatic tumor microenvironment: multi-omics insights into determinants of immunotherapy response

Li, M., 王婷婷, Zhang, Z., & Dongye, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1742855 · Cited by 9

Synergistic effects of radiotherapy and immunotherapy: improving oncological outcomes

Chen, X., Liu, W., Wang, Y., Yue, Z., Wang, J., Liu, Y., Xu, L., & Hu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1771355 · Cited by 8

The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review

Saleh, O. M., Albakri, K. A., Alabdallat, Y. J., Dajani, M., & Gazzar, W. B. E. (2021) · Biomarkers · doi:10.1080/1354750x.2021.2016973 · Cited by 8

Rewired Cellular Metabolic Profiles in Response to Metformin under Different Oxygen and Nutrient Conditions

Liu, S., Washio, J., Sato, S., Abiko, Y., Shinohara, Y., Kobayashi, Y., Otani, H., Sasaki, S., Wang, X., & Takahashi, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020989 · Cited by 8

Tumor Mechanics Meets Nanomedicine Mechanical Properties

Li, Z., Yang, X., & Li, Z. (2024) · Chemistry of Materials · doi:10.1021/acs.chemmater.3c02474 · Cited by 7

Pharmacologic HIF stabilization activates costimulatory receptor expression to increase antitumor efficacy of adoptive T cell therapy

Jackson, W., Yang, Y., Salman, S., Dordai, D. I., Lyu, Y., Datan, E., Drehmer, D., Huang, T. Y.-T., Hwang, Y., & Semenza, G. L. (2024) · Science Advances · doi:10.1126/sciadv.adq2366 · Cited by 9

Understanding Immune Cell Adaptation to Tumor Hypoxia for Maximized Therapeutic Efficacy of Immunotherapy: Biology and Non-invasive Imaging Application

Oh, T., Kim, M.-W., Kang, G.-S., Ye, S., Choi, C., Park, W., Hay, M. P., Hirata, H., & Ahn, G. (2025) · Cancer Research and Treatment · doi:10.4143/crt.2025.200 · Cited by 7

Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors

Lu, H., Teng, Z., Wang, J., & Zhang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583363 · Cited by 7

Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression

Montecchi, T., Nannini, G., Tommaso, D. D., Cassioli, C., Coppola, F., Ringressi, M. N., Carraro, F., Naldini, A., Taddei, A., Marotta, G., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03614-0 · Cited by 7

Identification of a basement membrane gene signature for predicting prognosis and estimating the tumor immune microenvironment in prostate cancer

Xie, T., Fu, D.-J., Li, K., Guo, J.-D., Xiao, Z., Li, Z., & Zhao, S. (2024) · Aging · doi:10.18632/aging.205445 · Cited by 7

Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen

Bujanda, Z. A. L., Chaimowitz, M. G., Armstrong, T. D., Foote, J. B., Emens, L. A., & Drake, C. G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1809926 · Cited by 7

Quantitative Phase Imaging Detecting the Hypoxia-Induced Patterns in Healthy and Neoplastic Human Colonic Epithelial Cells

Buzalewicz, I., Mrozowska, M., Kmiecik, A. M., Kulus, M., Haczkiewicz-Leśniak, K., Dzięgiel, P., Podhorska‐Okołów, M., & Zadka, Ł. (2022) · Cells · doi:10.3390/cells11223599 · Cited by 7

Orthogonal Optimization, Characterization, and In Vitro Anticancer Activity Evaluation of a Hydrogen Peroxide-Responsive and Oxygen-Reserving Nanoemulsion for Hypoxic Tumor Photodynamic Therapy

Liang, H., Wang, J., Zhou, Y. J., Shang, G., Guo, T., Tang, H., Li, J., Luo, Y., Zeng, X., Zeng, Z., et al. (2023) · Cancers · doi:10.3390/cancers15051576 · Cited by 7

Metabolic traits ruling the specificity of the immune response in different cancer types

Flerin, N. C., Cappellesso, F., Pretto, S., & Mazzone, M. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.10.011 · Cited by 7

Research progress on immunotherapeutics for triple-negative breast cancer from a single-cell perspective

Yuan, Z., Liu, Z., Zhou, M., Wen, H., & Li, B. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105111 · Cited by 6

Signaling new therapeutic opportunities: cytokines in prostate cancer

Chandran, E. B. A., Meininger, L., Karzai, F. H., & Madan, R. A. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2108701 · Cited by 6

Hypoxia induces dichotomous and reversible attenuation of T cell responses through reactive oxygen species-dependent phenotype redistribution and delay in lymphoblast proliferation

Maurya, D. K., Sharma, D., & Sandur, S. K. (2023) · Free Radical Research · doi:10.1080/10715762.2023.2178918 · Cited by 6

Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer

Zschaeck, S., Zöphel, K., Seidlitz, A., Zips, D., Kotzerke, J., Baumann, M. A., Troost, E. G. C., Löck, S., & Krause, M. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.10.030 · Cited by 6

Evofosfamide Enhances Sensitivity of Breast Cancer Cells to Apoptosis and Natural-Killer-Cell-Mediated Cytotoxicity Under Hypoxic Conditions

Das, S., Venkatesh, G. H., El‐Sayed, W., Khouzam, R. A., Mahmood, A. S., Nawafleh, H. H., Zeinelabdin, N. A., Zaarour, R. F., & Chouaïb, S. (2025) · Cancers · doi:10.3390/cancers17121988 · Cited by 5

Overcoming Therapeutic Resistance in Triple-Negative Breast Cancer: Targeting the Undrugged Kinome

Lee, C. H., Nguyen, T. M., Lee, Y., Choi, S. G., Nguyễn, P. N., Park, J. H., & Park, M. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010450 · Cited by 8

Extrinsic and Cell-Intrinsic Stress in the Immune Tumor Micro-Environment

Ummarino, A., Calà, N., & Allavena, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212403 · Cited by 6

Hypoxia-Induced VGF Promotes Cell Migration and Invasion in Prostate Cancer via the PI3K/Akt Axis

Wang, L., Zhang, T., Qian, Y., Wu, Y., Li, T., Zheng, Y., Luo, C., Wu, X., Chen, T., & Ou, L. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl25522 · Cited by 5

Comprehensive analysis of m6A modification in immune infiltration, metabolism and drug resistance in hepatocellular carcinoma

Shi, Y., Li, K., Yuan, Y., Wang, C., Yang, Z., Zuo, D., Niu, Y., Qiu, J., Li, B., Yuan, Y., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03307-3 · Cited by 5

Multi-omics Analysis Identifies Hypoxia Subtypes and S100A2 as an Immunosuppressive Factor in Cervical Cancer

Yang, J., Wan, S., Zhao, M., Cai, H., Gao, Y., & Wang, H. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01304-x · Cited by 5

Dynamic immuno-nanomedicines in oncology

Ling, H., Zhang, Q., Luo, Q., Ouyang, D., He, Z., Sun, J., & Sun, M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.052 · Cited by 4

Nanoformulation-based drug delivery systems for the treatment of gastric cancer: recent developments and future prospects

Zou, J., Chen, S., Liu, W., Wang, Y., Zheng, D., Sun, W., Xu, S., Wei, W., & Wang, S. (2025) · Nanoscale Horizons · doi:10.1039/d5nh00344j · Cited by 5

First-in-Human PET Imaging of Prostate Cancer Using [ 68 Ga]Ga-AZ-093 and Its Nitroimidazole-Conjugated Derivative [ 68 Ga]Ga-AZ-NI-093

Wang, G., Lai, Y., Chen, D., Jin, W., Luo, Y., Peng, Y., Kung, H. F., Zhu, L., Zang, J., Xu, N., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270703 · Cited by 4

Engineered macrophage membrane-mimicking nanodrugs activate cGAS/STING pathway to reverse tumor immune suppression after incomplete radiofrequency ablation

Zhang, W., Chen, L., Gao, L., Wu, Y., Jin, Z.-C., Chen, J.-J., An, Y., & Teng, G.-J. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03889-8 · Cited by 4

Biomarker-Driven Immunotherapy for Precision Medicine in Prostate Cancer

Ottini, A., Sepe, P., Beninato, T., Claps, M., Guadalupi, V., Verzoni, E., Giannatempo, P., Baciarello, G., de Braud, F., & Procopio, G. (2021) · Personalized Medicine · doi:10.2217/pme-2021-0079 · Cited by 4

Abstract 5011: Targeting hypoxia-induced immune suppression to overcome immunotherapy resistance in prostate cancer

Jayaprakash, P., Ai, M., Liu, A. J., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C. R., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-5011

Abstract 629: Combination hypoxia-specific chemotherapy and immunotherapy of prostate cancer

Ai, M., Bartkowiak, T., Jaiswal, A. R., Shah, K., Ager, C. R., Lerman, B., & Curran, M. A. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-629

Abstract IA11: Reversal of immunotherapy resistance through hypoxia reduction

Jayaprakash, P., Ai, M., & Curran, M. A. (2020) · Clinical Cancer Research · doi:10.1158/1557-3265.aacrahns19-ia11 · Cited by 1

705 Hypoxia-activated prodrugs with distinct mechanisms of action sensitize murine prostate tumors to immune checkpoint blockade

Jayaprakash, P., Bhanu, K. R., Azevedo, R. D., Hegde, S., Boda, A. R., Morrow, B., Patterson, A. V., Smaill, J. B., Fu, Z., Lin, X., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-sitc2024.0705

Abstract PR003: Hypoxia is an essential driver of immune suppression in the tumor microenvironment

Ai, M., Budhani, P., & Curran, M. A. (2016) · Cancer Immunology Research · doi:10.1158/2326-6074.cricimteatiaacr15-pr003